Reuters logo
BRIEF-Horizon Pharma estimates that its cash and cash equivalents were approximately $500 mln
January 10, 2017 / 2:15 PM / 10 months ago

BRIEF-Horizon Pharma estimates that its cash and cash equivalents were approximately $500 mln

Jan 10 (Reuters) - Horizon Pharma Plc

* Estimates that its cash and cash equivalents as of December 31 were approximately $500 million

* Estimates total principal amount of its indebtedness was approximately $1,945 million as of December 31

* Sees for 2016 fiscal year, net sales from its primary care medicines were approximately $600 million in aggregate Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below